|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
DE69917296T2
(de)
*
|
1998-08-20 |
2005-05-25 |
Smithkline Beecham Corp. |
Neue substituierte triazolverbindungen
|
|
EP1126852B1
(en)
|
1998-11-04 |
2004-01-21 |
SmithKline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ATE556713T1
(de)
|
1999-01-13 |
2012-05-15 |
Bayer Healthcare Llc |
Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
CN1348370A
(zh)
|
1999-04-15 |
2002-05-08 |
布里斯托尔-迈尔斯斯奎布公司 |
环状蛋白酪氨酸激酶抑制剂
|
|
EP1233950B1
(en)
|
1999-11-23 |
2005-10-05 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
|
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
|
JP2003514900A
(ja)
|
1999-11-23 |
2003-04-22 |
スミスクライン・ビーチャム・コーポレイション |
CSBP/p38キナーゼ阻害剤としての3,4−ジヒドロ−(1H)−キナゾリン−2−オン化合物
|
|
ES2230171T3
(es)
|
1999-11-23 |
2005-05-01 |
Smithkline Beecham Corporation |
Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
|
|
DE60136530D1
(de)
|
2000-03-01 |
2008-12-24 |
Janssen Pharmaceutica Nv |
2,4-disubstituierte thiazolyl derivate
|
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
|
EP2404603A1
(en)
*
|
2000-10-23 |
2012-01-11 |
Glaxosmithkline LLC |
Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
|
|
DK1347971T3
(da)
|
2000-12-21 |
2006-05-15 |
Bristol Myers Squibb Co |
Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
EP2036891A3
(en)
|
2001-06-11 |
2009-03-25 |
Vertex Pharmaceuticals Incorporated |
Isoquinoline inhibitors of P38
|
|
HN2002000156A
(es)
|
2001-07-06 |
2003-11-27 |
Inc Agouron Pharmaceuticals |
Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
|
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
KR101010905B1
(ko)
|
2002-01-18 |
2011-01-25 |
아스텔라스세이야쿠 가부시키가이샤 |
2-아실아미노티아졸 유도체 또는 그 염
|
|
EP1474393A1
(en)
|
2002-02-11 |
2004-11-10 |
Bayer Pharmaceuticals Corporation |
Aryl ureas as kinase inhibitors
|
|
AU2003209116A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
|
ATE485275T1
(de)
*
|
2002-02-12 |
2010-11-15 |
Glaxosmithkline Llc |
Nicotinamide und deren verwendung als p38 inhibitoren
|
|
BR0309669A
(pt)
*
|
2002-04-23 |
2005-03-01 |
Bristol Myers Squibb Co |
Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
|
|
US7220764B2
(en)
*
|
2002-06-17 |
2007-05-22 |
The Pennsylvania State University Research Foundation |
Sphingosine kinase inhibitors
|
|
JP2005538066A
(ja)
|
2002-07-09 |
2005-12-15 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
新規な抗コリン作用薬及びp38キナーゼ阻害剤を用いた新規な医薬組成物
|
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
|
CN101723891A
(zh)
|
2003-02-10 |
2010-06-09 |
沃泰克斯药物股份有限公司 |
通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
|
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
PT1636585E
(pt)
|
2003-05-20 |
2008-03-27 |
Bayer Pharmaceuticals Corp |
Diarilureias com actividade inibidora de cinase
|
|
WO2005000298A2
(en)
*
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
5-membered heterocycle-based p-38 inhibitors
|
|
NZ544920A
(en)
|
2003-07-23 |
2009-11-27 |
Bayer Healthcare Llc |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
|
US7244441B2
(en)
*
|
2003-09-25 |
2007-07-17 |
Scios, Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
|
WO2005032551A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
EP1865959A2
(en)
*
|
2005-03-25 |
2007-12-19 |
Glaxo Group Limited |
Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
|
|
PE20061351A1
(es)
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
|
|
BRPI0608910A2
(pt)
*
|
2005-05-09 |
2010-02-17 |
Achillion Pharmaceuticals Inc |
uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
|
|
EP1885181A2
(en)
*
|
2005-05-23 |
2008-02-13 |
Smithkline Beecham Corporation |
Inhibition of p38 mark for treatment of obesity
|
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
|
IL169855A
(en)
*
|
2005-07-25 |
2014-05-28 |
Elta Systems Ltd |
A system and method for locating a receiver location
|
|
PL1907382T3
(pl)
|
2005-07-26 |
2016-01-29 |
Bial Portela & Ca Sa |
Pochodne nitrokatecholowe jako inhibitory COMT
|
|
EP1996565A2
(en)
*
|
2006-03-08 |
2008-12-03 |
Achillion Pharmaceuticals, Inc. |
Substituted aminothiazole derivatives with anti-hcv activity
|
|
EP1845097A1
(en)
*
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
WO2008021283A2
(en)
*
|
2006-08-08 |
2008-02-21 |
Akarx, Inc. |
Compositions and methods for increasing blood platelet levels in humans
|
|
CA2678391C
(en)
|
2007-01-31 |
2017-01-17 |
David Alexander Learmonth |
Dosage regimen for comt inhibitors
|
|
EP2131858A4
(en)
*
|
2007-03-20 |
2011-11-23 |
Cadila Pharmaceuticals Ltd |
P38 INHIBITORS
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
MX2009012613A
(es)
*
|
2007-05-22 |
2010-04-21 |
Achillion Pharmaceuticals Inc |
Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
|
|
BRPI0908340A2
(pt)
*
|
2008-02-28 |
2018-12-26 |
Bial Portela & Ca Sa |
composição farmacêutica para fármacos pouco solúveis
|
|
RU2010139315A
(ru)
|
2008-03-17 |
2012-04-27 |
Биал - Портела Энд Ка., С.А. (Pt) |
Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
|
|
US8106209B2
(en)
*
|
2008-06-06 |
2012-01-31 |
Achillion Pharmaceuticals, Inc. |
Substituted aminothiazole prodrugs of compounds with anti-HCV activity
|
|
WO2010077955A1
(en)
|
2008-12-17 |
2010-07-08 |
The Scripps Research Institute |
Generation and maintenance of stem cells
|
|
EP2396302A2
(en)
*
|
2009-02-13 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
|
|
PT2413913T
(pt)
*
|
2009-04-01 |
2022-06-09 |
Bial Portela & Ca Sa |
Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar
|
|
RU2701731C2
(ru)
|
2009-04-01 |
2019-10-01 |
Биал-Портела Энд Ка, С.А. |
Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
|
|
EP2464352A1
(en)
*
|
2009-08-14 |
2012-06-20 |
Eisai Inc. |
Use of e5501 for stimulating platelet production
|
|
DK2648516T3
(da)
|
2010-12-06 |
2019-01-02 |
Aclaris Therapeutics Inc |
Substituerede pyridinon-pyridinylforbindelser
|
|
WO2012078674A1
(en)
|
2010-12-06 |
2012-06-14 |
Confluence Life Sciences, Inc. |
Substituted indole/indazole-pyrimidinyl compounds
|
|
US8563558B2
(en)
|
2010-12-06 |
2013-10-22 |
Confluence Life Sciences, Inc. |
Substituted pyridine urea compounds
|
|
US9359300B2
(en)
|
2010-12-06 |
2016-06-07 |
Confluence Life Sciences, Inc. |
Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
WO2013086208A1
(en)
|
2011-12-06 |
2013-06-13 |
Confluence Life Sciences, Inc. |
Substituted pyrimidinone-phenyl-pyrimidinyl compounds
|
|
EP3604299B1
(en)
|
2011-12-13 |
2023-07-26 |
Bial-Portela & CA, S.A. |
Chemical compound useful as intermediate for preparing a catechol-0-methyl transferase inhibitor
|
|
EP2843049B1
(en)
*
|
2012-04-27 |
2018-04-11 |
Keio University |
Neuronal differentiation promoter
|
|
SI3003039T1
(sl)
|
2013-06-07 |
2021-08-31 |
Aclaris Therapeutics, Inc. |
Metil/fluoro-piridinil-metoksi substituirane spojine piridinon-piridinila in fluoro-pirimidinil-metoksi substituirane spojine piridinon-piridinila
|
|
JP2018500300A
(ja)
|
2014-11-28 |
2018-01-11 |
ノヴィファーマ,エス.アー. |
パーキンソン病を遅延させるための医薬
|
|
ES2908041T3
(es)
|
2015-10-27 |
2022-04-27 |
Childrens Hospital Med Ct |
Uso de inhibidores de MAPK para reducir la pérdida de células madre hematopoyéticas durante el cultivo ex vivo y la manipulación genética
|
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
|
EP3692144A1
(en)
|
2017-10-05 |
2020-08-12 |
Fulcrum Therapeutics, Inc. |
Use of p38 inhibitors to reduce expression of dux4
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
US10889548B2
(en)
|
2018-03-26 |
2021-01-12 |
Clear Creek Bio, Inc. |
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
|
RU2709496C1
(ru)
*
|
2019-08-01 |
2019-12-18 |
Марат Феликсович Фазылов |
Способ получения аватромбопага
|
|
US20210315880A1
(en)
|
2020-03-20 |
2021-10-14 |
Clear Creek Bio, Inc. |
Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
|
|
EP4125891A4
(en)
|
2020-03-27 |
2024-08-21 |
Aclaris Therapeutics, Inc. |
PROCESS, COMPOSITIONS AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS
|
|
WO2022195579A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
|